The Treatment of Malignant Meningioma with Verotoxin
Malignant meningiomas (MMs) are aggressive intracranial neoplasms with a 75% 5-year recurrence rate. Verotoxin 1 (VTi) is an Escherichia coli toxin, which has recently been shown to have anti-neoplastic action by targeting the globotriosylceramide (Gb3) glycolipid on tumor cells and tumor neovascul...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2002-01-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558602800252 |
id |
doaj-917f50e91b79458ab2296255c6835175 |
---|---|
record_format |
Article |
spelling |
doaj-917f50e91b79458ab2296255c68351752020-11-25T00:59:58ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55861522-80022002-01-014430431110.1038/sj.neo.7900243The Treatment of Malignant Meningioma with VerotoxinBodour Salhia0James T. Rutka1Clifford Lingwood2Anita Nutikka3Wouter R. Van Furth4Arthur and Sonia Labatt Brain Tumour Research Center, Division of Neurosurgery, The University of Toronto, Toronto, Ontario, CanadaArthur and Sonia Labatt Brain Tumour Research Center, Division of Neurosurgery, The University of Toronto, Toronto, Ontario, CanadaThe Department of Infection, Immunity, Injury and Repair, The Hospital for Sick Children, The University of Toronto, Toronto, Ontario, CanadaThe Department of Infection, Immunity, Injury and Repair, The Hospital for Sick Children, The University of Toronto, Toronto, Ontario, CanadaThe Department of Neurosurgery, University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands Malignant meningiomas (MMs) are aggressive intracranial neoplasms with a 75% 5-year recurrence rate. Verotoxin 1 (VTi) is an Escherichia coli toxin, which has recently been shown to have anti-neoplastic action by targeting the globotriosylceramide (Gb3) glycolipid on tumor cells and tumor neovasculature. To investigate the potential use of VTi as a clinical agent for MM, we initially tested 16 meningiomas for Gb3 expression. Nine of 11 MMs (82%), but only one of five benign meningiomas (20%), were positive for Gb3. An orthotopic xenograft model was used to test the efficacy of VTi treatment for MM. We first demonstrated that Gb3 was highly expressed by the MM cell line, IOMM-Lee, and that this cell line was highly sensitive to VTi treatment in vitro. A single intratumoral injection of VTi significantly improved survival in nude mice harboring intracranial tumours (P<.0001). Factor-eight immunostaining of tumours harvested from VTi-treated animals revealed a marked reduction in the tumour microvascular density. In addition, the tumors of VTi-treated animals displayed increased apoptosis by TUNEL analysis and showed a significant decrease in cell proliferation, as determined by MIB-5 immunostaining. VTi treatment of MM is effective in our orthotopic xenograft model, and warrants further exploration as a potential treatment for these highly anaplastic and aggressive neoplasms. http://www.sciencedirect.com/science/article/pii/S1476558602800252apoptosisIOMM-Leemeningiomamicrovascular densityverotoxin |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bodour Salhia James T. Rutka Clifford Lingwood Anita Nutikka Wouter R. Van Furth |
spellingShingle |
Bodour Salhia James T. Rutka Clifford Lingwood Anita Nutikka Wouter R. Van Furth The Treatment of Malignant Meningioma with Verotoxin Neoplasia: An International Journal for Oncology Research apoptosis IOMM-Lee meningioma microvascular density verotoxin |
author_facet |
Bodour Salhia James T. Rutka Clifford Lingwood Anita Nutikka Wouter R. Van Furth |
author_sort |
Bodour Salhia |
title |
The Treatment of Malignant Meningioma with Verotoxin |
title_short |
The Treatment of Malignant Meningioma with Verotoxin |
title_full |
The Treatment of Malignant Meningioma with Verotoxin |
title_fullStr |
The Treatment of Malignant Meningioma with Verotoxin |
title_full_unstemmed |
The Treatment of Malignant Meningioma with Verotoxin |
title_sort |
treatment of malignant meningioma with verotoxin |
publisher |
Elsevier |
series |
Neoplasia: An International Journal for Oncology Research |
issn |
1476-5586 1522-8002 |
publishDate |
2002-01-01 |
description |
Malignant meningiomas (MMs) are aggressive intracranial neoplasms with a 75% 5-year recurrence rate. Verotoxin 1 (VTi) is an Escherichia coli toxin, which has recently been shown to have anti-neoplastic action by targeting the globotriosylceramide (Gb3) glycolipid on tumor cells and tumor neovasculature. To investigate the potential use of VTi as a clinical agent for MM, we initially tested 16 meningiomas for Gb3 expression. Nine of 11 MMs (82%), but only one of five benign meningiomas (20%), were positive for Gb3. An orthotopic xenograft model was used to test the efficacy of VTi treatment for MM. We first demonstrated that Gb3 was highly expressed by the MM cell line, IOMM-Lee, and that this cell line was highly sensitive to VTi treatment in vitro. A single intratumoral injection of VTi significantly improved survival in nude mice harboring intracranial tumours (P<.0001). Factor-eight immunostaining of tumours harvested from VTi-treated animals revealed a marked reduction in the tumour microvascular density. In addition, the tumors of VTi-treated animals displayed increased apoptosis by TUNEL analysis and showed a significant decrease in cell proliferation, as determined by MIB-5 immunostaining. VTi treatment of MM is effective in our orthotopic xenograft model, and warrants further exploration as a potential treatment for these highly anaplastic and aggressive neoplasms.
|
topic |
apoptosis IOMM-Lee meningioma microvascular density verotoxin |
url |
http://www.sciencedirect.com/science/article/pii/S1476558602800252 |
work_keys_str_mv |
AT bodoursalhia thetreatmentofmalignantmeningiomawithverotoxin AT jamestrutka thetreatmentofmalignantmeningiomawithverotoxin AT cliffordlingwood thetreatmentofmalignantmeningiomawithverotoxin AT anitanutikka thetreatmentofmalignantmeningiomawithverotoxin AT wouterrvanfurth thetreatmentofmalignantmeningiomawithverotoxin AT bodoursalhia treatmentofmalignantmeningiomawithverotoxin AT jamestrutka treatmentofmalignantmeningiomawithverotoxin AT cliffordlingwood treatmentofmalignantmeningiomawithverotoxin AT anitanutikka treatmentofmalignantmeningiomawithverotoxin AT wouterrvanfurth treatmentofmalignantmeningiomawithverotoxin |
_version_ |
1725215045084774400 |